-

Posts Tagged ‘dolutegravir’

Dolutegravir and the 88% Rule

Paul Sax • October 28th, 2012

Categories: Health Care, HIV, Patient Care, Research

(3 votes, average: 4.67 out of 5)

In the latest treatment-naive trials of elvitegravir and dolutegravir, there’s a striking consistency in the results of the “test” regimen. Here are the studies, with the percentage of responders by treatment arm: Study 102:  TDF/FTC/EFV (84%) vs. TDF/FTC/EVG/c (88%) — non-inferior Study 103:  TDF/FTC + ATV/r (87%) vs. TDF/FTC/EVG/c (90%) — non-inferior SPRING-2:  TDF/FTC or [...]

Really Rapid Review — 2012 International AIDS Conference, Washington, DC

Paul Sax • August 1st, 2012

Categories: Health Care, HIV, Infectious Diseases, Research

(14 votes, average: 4.29 out of 5)

Last week’s International AIDS Conference in Washington got plenty of media attention, mostly because it was the first time in umpteen years that it was held in the United States, the delay between meetings due to our absurd (and now repealed) immigration laws regarding HIV. (Quick trivia question — where was the conference supposed to [...]

Sizzling Summer Serratias

Paul Sax • July 16th, 2012

Categories: Health Care, Infectious Diseases, Misc

(3 votes, average: 5.00 out of 5)

Several ID/HIV items to contemplate as the heat really kicks in here in the torrid USA: TDF/FTC approved for pre-exposure prophylaxis. The challenging issues of defining the best candidates for this strategy — and finding the providers to prescribe it — still remain, but FDA approval should at least help justify insurance coverage if clinicians [...]

CROI 2012 Really Rapid Review — with CROI 2013 Dates!

Paul Sax • March 15th, 2012

Categories: Health Care, Infectious Diseases, Patient Care, Research

(10 votes, average: 4.70 out of 5)

Some highly subjective highlights — a Really Rapid Review™– from this year’s Number One Greatest Super Scientific HIV Conference, the 19th Conference on Retroviruses and Opportunistic Infections (CROI), which ended last week in Seattle: Need more evidence that maintaining a CD4 cell count > 500 is beneficial? This compelling analysis from the SMART and ESPRIT  studies found [...]

Really Rapid Review — IAS 2011 Rome

Paul Sax • July 28th, 2011

Categories: Health Care, HIV, Infectious Diseases, Research

(8 votes, average: 4.50 out of 5)

Just back from IAS 2011 (which was followed, I’m thrilled to say, with a visit to perhaps the most beautiful region in the world). Here is a Really Rapid Review™ of the meeting, with apologies ahead of time for lack of organization and (even more likely) leaving out something important.  FYI, the abstracts are online [...]